Evidence map›Paper›PMID 33313667›Full record

ArticleAmerican journal of clinical pathology2021

The Value of Artificial Intelligence in Laboratory Medicine.

Ketan Paranjape, Michiel Schinkel, Richard D Hammer, Bo Schouten, R S Nannan Panday, Paul W G Elbers, Mark H H Kramer, Prabath Nanayakkara

Abstract read
In one paragraph

Article in American journal of clinical pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Artificial Intelligence in Biomedical Sciences: A Scoping Review.British journal of biomedical science · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Building the Model.Archives of pathology & laboratory medicine · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ketan ParanjapeAmsterdam UMC.ORCID 0000-0001-5330-8330
Michiel SchinkelSection Acute Medicine, Department of Internal Medicine, Amsterdam UMC.
Richard D HammerDepartment of Pathology and Anatomical Sciences, University of Missouri School of Medicine, Columbia.
Bo SchoutenAmsterdam UMC.
R S Nannan PandaySection Acute Medicine, Department of Internal Medicine, Amsterdam UMC.
Paul W G ElbersDepartment of Intensive Care Medicine, Amsterdam Medical Data Science, Amsterdam Cardiovascular Science, Amsterdam Infection and Immunity Institute, Amsterdam UMC.
Mark H H KramerBoard of Directors, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
Prabath NanayakkaraSection Acute Medicine, Department of Internal Medicine, Amsterdam UMC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAs laboratory medicine continues to undergo digitalization and automation, clinical laboratorians will likely be confronted with the challenges associated with artificial intelligence (AI). Understanding what AI is good for, how to evaluate it, what are its limitations, and how it can be implemented are not well understood. With a survey, we aimed to evaluate the thoughts of stakeholders in laboratory medicine on the value of AI in the diagnostics space and identify anticipated challenges and solutions to introducing AI.

methodsWe conducted a web-based survey on the use of AI with participants from Roche's Strategic Advisory Network that included key stakeholders in laboratory medicine.

resultsIn total, 128 of 302 stakeholders responded to the survey. Most of the participants were medical practitioners (26%) or laboratory managers (22%). AI is currently used in the organizations of 15.6%, while 66.4% felt they might use it in the future. Most had an unsure attitude on what they would need to adopt AI in the diagnostics space. High investment costs, lack of proven clinical benefits, number of decision makers, and privacy concerns were identified as barriers to adoption. Education in the value of AI, streamlined implementation and integration into existing workflows, and research to prove clinical utility were identified as solutions needed to mainstream AI in laboratory medicine.

conclusionsThis survey demonstrates that specific knowledge of AI in the medical community is poor and that AI education is much needed. One strategy could be to implement new AI tools alongside existing tools.

Indexed as

Artificial IntelligenceLaboratoriesSurveys and QuestionnairesAgedAged, 80 and overAge FactorsDelivery of Health CareFemaleHumansMaleMiddle AgedArtificial intelligenceDiagnosticsLaboratory medicineMedical education

Identifiers

PMID33313667
PMCPMC8130876

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.